United Therapeutics (NASDAQ:UTHR) Hits New 1-Year High on Analyst Upgrade

Shares of United Therapeutics Corporation (NASDAQ:UTHR) reached a new 52-week high during mid-day trading on Tuesday after HC Wainwright raised their price target on the stock from $600.00 to $660.00. HC Wainwright currently has a buy rating on the stock. United Therapeutics traded as high as $607.89 and last traded at $588.36, with a volume of 1721854 shares changing hands. The stock had previously closed at $522.83.

UTHR has been the topic of a number of other reports. Cantor Fitzgerald raised their price objective on United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, March 12th. Royal Bank Of Canada boosted their target price on United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. UBS Group lifted their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $586.00.

Insiders Place Their Bets

In related news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $471.91, for a total transaction of $10,617,975.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $489.91, for a total value of $4,654,145.00. Following the transaction, the chief executive officer directly owned 130 shares in the company, valued at $63,688.30. This trade represents a 98.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 333,820 shares of company stock worth $165,495,478 over the last quarter. 10.30% of the stock is owned by corporate insiders.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 Phase 3 success — The pivotal TETON‑1 study met its primary endpoint, showing a clinically meaningful FVC improvement (Hodges‑Lehmann estimate ~130.1 mL vs placebo at 52 weeks), supporting Tyvaso’s potential expansion into IPF and a likely regulatory path. BusinessWire: TETON‑1 Results
• Positive Sentiment: Wall Street upgrades and target lifts — Multiple firms raised price targets (TD Cowen, HC Wainwright, BofA, TD Cowen to ~$660 among others), reflecting materially higher revenue/market‑expansion assumptions if Tyvaso wins an IPF label. TickerReport: HC Wainwright Raise
• Positive Sentiment: Buyback / ASR and ralinepag momentum — Recent company buyback authorizations (including accelerated share repurchase activity) and positive Phase 3 ralinepag data (PAH) add to near‑term shareholder‑return dynamics and reduce share count risk. QuiverQuant: Buyback & Ralinepag
• Neutral Sentiment: Heavy call‑option activity and volume — Unusually large call buying and above‑average equity volume indicate speculative positioning and short covering; this can amplify moves short term but is not a fundamental read‑through by itself.
• Neutral Sentiment: Mixed analyst stances — Some firms raised targets but kept neutral/equal‑weight ratings (e.g., Wells Fargo, BofA), signaling differing views on how much IPF uptake and pricing convert to durable earnings. 24/7 Wall St.: Dual Target Hikes
• Negative Sentiment: Valuation and execution risk cautions — Some analysts note that strong trial momentum is partially offset by high valuation and execution/regulatory risk (commercial rollout, payer uptake), which could limit further multiple expansion. TipRanks: Balanced View
• Negative Sentiment: Large insider selling flagged — Public filings compiled by data providers show extensive insider sales over recent months; investors often view concentrated insider selling as a negative signal to monitor. QuiverQuant: Insider Activity
• Negative Sentiment: Questions about sustainability of the move — Some market commentaries (and earnings‑estimate trends) warn the post‑trial pop may not sustain unless follow‑on commercialization, label, and payer access dynamics become clearer. Zacks: Will Strength Last?

Institutional Trading of United Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Clearstead Advisors LLC lifted its stake in United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 23 shares during the period. Independent Advisor Alliance grew its position in shares of United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock worth $406,000 after buying an additional 27 shares during the period. Bessemer Group Inc. grew its position in shares of United Therapeutics by 2.6% during the 3rd quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after buying an additional 28 shares during the period. Florida Financial Advisors LLC increased its stake in shares of United Therapeutics by 5.4% in the 4th quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock valued at $268,000 after acquiring an additional 28 shares during the last quarter. Finally, NDVR Inc. increased its stake in shares of United Therapeutics by 5.1% in the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

The business’s 50-day moving average is $500.92 and its two-hundred day moving average is $476.29. The firm has a market capitalization of $25.99 billion, a price-to-earnings ratio of 21.25, a P/E/G ratio of 2.12 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The firm had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter in the previous year, the company earned $6.19 earnings per share. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. Analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.